^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
naratuximab emtansine (DEBIO 1562)
i
Other names: DEBIO 1562, K7153A-SMCC-DM1, K7153A, IMGN-529, IMGN529
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
AbbVie, Debiopharm
Drug class:
Microtubule inhibitor, CD37-targeted antibody-drug conjugate
Related drugs:
over1year
Predicting response to naratuximab emtansine, an anti-CD37 antibody-drug conjugate (ADC), in combination with rituximab in Diffuse Large B Cell Lymphoma (DLBCL), by analyzing the spatial arrangement of CD37 and CD20 positive cells using deep learning (AACR-NCI-EORTC 2022)
DL analysis of the co-expression and spatial arrangement of CD37 and CD20 positive cells in pre-treatment biopsies of DLBCL patients could potentially be used as a predictive biomarker for a response to a combination treatment of naratuximab emtansine and rituximab in DLBCL, and may improve patient stratification for further clinical trials.
Combination therapy
|
CD20 (Membrane Spanning 4-Domains A1)
|
CD20 positive
|
Rituxan (rituximab) • naratuximab emtansine (DEBIO 1562)
2years
Predicting response to naratuximab emtansine, an anti-CD37 antibody-drug conjugate (ADC), in combination with rituximab in diffuse large B-cell lymphoma (DLBCL), by analyzing the spatial arrangement of CD37 and CD20 positive cells using deep learning. (ASCO 2022)
DL analysis of the co-expression and spatial arrangement of CD37 and CD20 in pre-treatment biopsies of DLBCL patients could potentially be used as a predictive biomarker for a response to a combination treatment of anti-CD37 and anti-CD20 drugs in DLBCL, and may improve patient stratification for further clinical trials.
Combination therapy
|
CD20 (Membrane Spanning 4-Domains A1)
|
CD20 positive
|
Rituxan (rituximab) • naratuximab emtansine (DEBIO 1562)
Share via
